Transcenta Holding Ltd

06628

Company Profile

  • Business description

    Transcenta Holding Ltd is a clinical-stage biopharmaceutical company with fully integrated capacities in discovery, research, development, manufacturing, and business development. It is developing approximately fifteen therapeutic antibody molecules for oncology and selected non-oncology indications, including bone and kidney disorders. The company's drug development pipeline includes Osemitamab (TST001), TST002 (Blosozumab), TST003, TST006, MSB2311, MSB0254, TST808, and others to treat various oncology and non-oncology complications in different ways. Geographically, the company operates in China (the PRC), which is its key revenue market, and the United States of America.

  • Contact

    218 Xinghu Street
    B6-501, Biobay
    Suzhou215123
    CHN

    T: +86 51267079200

    https://www.transcenta.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    184

Stocks News & Analysis

stocks

A collection of our best stock opportunities

Our latest articles about where we see opportunities in the market.
stocks

Morningstar analyst reacts to Macquarie Group’s earnings

Banking Analyst Nathan Zaia’s analysis of MQG’s results.
stocks

Undervalued ASX share showing progress in global efforts

More clarity on the path forward in the UK.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,963.5029.200.33%
CAC 407,800.8833.70-0.43%
DAX 4023,970.36247.14-1.02%
Dow JONES (US)44,857.1244.80-0.10%
FTSE 1009,081.4438.87-0.43%
HKSE25,562.13173.780.68%
NASDAQ21,168.7660.450.29%
Nikkei 22540,998.27457.96-1.10%
NZX 50 Index12,910.7457.280.45%
S&P 5006,390.231.590.02%
S&P/ASX 2008,697.7030.800.36%
SSE Composite Index3,597.944.280.12%

Market Movers